489 related articles for article (PubMed ID: 25929310)
1. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
[TBL] [Abstract][Full Text] [Related]
2. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
[TBL] [Abstract][Full Text] [Related]
3. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
Santagostino E
Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
[TBL] [Abstract][Full Text] [Related]
4. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
7. IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A.
Kadar JG; Schuster J; Hunzelmann N
Haemophilia; 2007 Jan; 13(1):104-5. PubMed ID: 17212734
[TBL] [Abstract][Full Text] [Related]
8. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
[TBL] [Abstract][Full Text] [Related]
9. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
[TBL] [Abstract][Full Text] [Related]
10. Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.
Lövgren KM; Søndergaard H; Skov S; Wiinberg B
Haemophilia; 2016 Sep; 22(5):772-9. PubMed ID: 27439658
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
12. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients.
Schep SJ; Fischer K; Boes M; Schutgens REG
Haemophilia; 2023 Jul; 29(4):1039-1048. PubMed ID: 37276354
[TBL] [Abstract][Full Text] [Related]
13. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
14. Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.
Bravo MI; Pérez A; Raventós A; Grancha S; Jorquera JI; Butta NV; Álvarez-Román MT; Costa M; Willis T; Jiménez-Yuste V
Haemophilia; 2022 Sep; 28(5):737-744. PubMed ID: 35654086
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
Haemophilia; 2015 Sep; 21(5):686-92. PubMed ID: 25708525
[TBL] [Abstract][Full Text] [Related]
16. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
Ettingshausen CE; Kreuz W
Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor development in non-severe haemophilia across Europe.
Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
[TBL] [Abstract][Full Text] [Related]
19. Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.
Grosbois SS; Brionne MF; de Longcamp AL; Gautier P; V Kaveri S; Borel-Derlon A; Repessé Y
Haemophilia; 2013 Mar; 19(2):322-9. PubMed ID: 23216758
[TBL] [Abstract][Full Text] [Related]
20. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
Shima M; Sawamoto Y; Nakai H; Kamisue S; Murakami T; Morichika S; Tanaka I; Hayashi K; Yoshioka A
Int J Hematol; 1995 Jul; 62(1):35-43. PubMed ID: 7670006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]